VERX - Vertex, Inc.
Vertex Pharmaceuticals is slowly but surely expanding beyond its highly successful core therapeutic area. Regeneron has successfully rebounded after facing biosimilar competition for a key growth driver, and it boasts several attractive pipeline candidates.
KING OF PRUSSIA, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), the Decision-to-Defense™ global indirect tax and compliance company, today announced that Chris Young, President and Chief Executive Officer, and John Schwab, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Communacopia + Technology Conference on Wednesday, September 9, 2026 at 1:05 PM Pacific Time.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases. Vertex also announced the expansion of its executive leadership team, in support of the Company's continued growth and diversification. Completion of Acquisition of Crinetic.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 4:30 p.m. EDT. Susie Lisa and Manisha Pai will also participate in a fireside chat at the 2026 Cantor G.
Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.
Explore the exciting world of Vertex Pharmaceuticals (VRTX +1.44%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Vertex Pharmaceuticals' business could be in trouble if it faces competition in its core market. However, one of the company's most important potential competitors recently hit a clinical setback.
Vertex Pharmaceuticals appears likely to continue to dominate its core therapeutic area. The company is slowly developing and launching medicines in other markets.
I was too cautious previously on Vertex Pharmaceuticals' prospects. Revenue from its cystic fibrosis franchise grew 10% quarter-on-quarter and 10.6% year-on-year to about $3.21 billion in Q2. On July 6, VRTX announced the acquisition of Crinetics Pharmaceuticals for about $10 billion, thereby strengthening its position in the endocrinology drugs market.
KING OF PRUSSIA, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today released its 2026 Mid-Year U.S. Sales Tax Rates and Rules Report, revealing that the combined average U.S. sales tax rate climbed for the first time in four years to reach a 10-year high of 10.1881%.
Vertex Pharmaceuticals could face competition in its most important market by far. The company is preparing for that by diversifying its lineup and pipeline.
Vertex (VERX) could produce exceptional returns because of its solid growth attributes.
Its sales rose at a double-digit rate; net profit growth was more modest. There's another development with the company more worth monitoring, however.
Vertex Inc (NASDAQ:VERX) reported upbeat earnings for the second quarter on Monday.
KING OF PRUSSIA, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ: VERX), the Decision-to-Defense™ global indirect tax and compliance company, today announced three additions to its leadership team to support its next phase of growth: Chatelle Lynch as Chief People Officer, Carlos Mercuriali as Senior Vice President and Regional Manager of Europe, and Bala Chandran as Chief Product and Technology Officer.
Vertex Pharmaceuticals is executing a pivotal transition year, evolving from a CF-dominated biotech to a multi-franchise growth platform. 2Q26 revenue rose 12% to $3.33 billion, with strong CF performance and early scaling of Casgevy and Journvax supporting raised FY26 guidance to $13.1–$13.2 billion. VRTX is aggressively reinvesting in pipeline and commercial launches, leveraging a $13.6 billion cash position and diversifying with the Crinetics acquisition.
Vertex, Inc. (VERX) Q2 2026 Earnings Call Transcript
Vertex NASDAQ: VERX reported second-quarter revenue at the high end of its guidance range and raised its full-year adjusted EBITDA outlook, as the tax technology company cited cost discipline, stable customer retention and growing demand for e-invoicing solutions.
Vertex Pharmaceuticals NASDAQ: VRTX reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising contributions from newer products CASGEVY and JOURNAVX.
The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.